Late-Window Stroke: Hyperglycemia Doesn’t Alter EVT Benefit
The International Journal of Stroke recently shared a post on X:
”Just Accepted! Study in those with acute ischemic stroke and large vessel occlusion of the anterior circulation. Results show hyperglycaemia does not modify the efficacy of endovascular therapy in the late time window.”
Read the full article here.
Hyperglycemia has long been the unwelcome guest at the stroke table, often associated with worse outcomes and suspected of meddling with treatment effects—especially in early endovascular therapy (EVT).
Naturally, one might expect it to play a similarly disruptive role in patients treated in the late window (6 to 24 hours after symptom onset or last known well).
But in the study of anterior circulation large vessel occlusion stroke, Clemens Kersten et al. showed that hyperglycemia had surprisingly little to say.
Regardless of admission glucose levels, the benefit of EVT remained unchanged.
In conclusion, no evidence that admission glucose or hyperglycemia modifies the benefit of EVT in this population, suggesting EVT efficacy remains consistent across a range of glucose levels in the late window setting.
Stay updated on the advancements in science in the field of thrombosis with Hemostasis Today.
-
Oct 6, 2025, 04:10EAHAD PT Committee Chair Ruth Elise Is Contributing to The Discussion On Joint Health and Mobility At EHC 2025
-
Oct 6, 2025, 03:44Caitlin Raymond: When We Talk About Plasma Exchange, Most Discussions Stop At What We’re Removing, But That’s Only Half The Story
-
Oct 5, 2025, 11:38Marc Vasse: Very Honored to Have Been Invited to Moderate the Session "Haemostasis and Oncology'' at 25th Moroccan Days of Clinical Biology
-
Oct 5, 2025, 08:32Maria Elisa Mancuso: During Day 2 of the Annual EHC Conference We Discussed Very Rare Bleeding Disorders!
-
Oct 5, 2025, 08:21Mattia Galli Gives a Talk on Pharma Pulse About "De-escalation" of Antiplatelet Therapy in ACS
-
Oct 6, 2025, 03:48New Insights On Pre-Existing AAV5 Abs in Haemophilia B Gene Therapy
-
Oct 6, 2025, 03:40Emmanuel J Favaloro and Leonardo Pasalic's Commentary On Acquired von Willebrand Syndrome in Children
-
Oct 5, 2025, 12:43Nita Radhakrishnan and Colleagues on Tertiary Prophylaxis with Extended Half-life Factor in LMIC Settings
-
Oct 5, 2025, 12:15Laura Avila and Colleagues on Childhood DVT: Upper Extremity (UE) Post-thrombotic Syndrome (PTS)
-
Oct 5, 2025, 11:54Laura Girardi on Anticoagulant Treatment for Isolated Distal DVT: Finally Our Official Paper Is Out!
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 6, 2025, 03:57Mattia Galli - Nominated Among The Top 200 of 200,000 Leading Researchers Worldwide for The 2025 USERN Prize!
-
Oct 6, 2025, 03:46Marilena Vrana: I Want to Thank Grifols Deutschland for The Opportunity to Visit Their Premises and Biotest AG Manufacturing Facility in Dreieich
-
Oct 6, 2025, 03:43Maha Othman: Real-World Learning Is Essential in Preparing Our Future Nurses!
-
Oct 5, 2025, 12:29Miguel Crato: I Feel I Must Always Be Strong, But That Wears Me Down
-
Oct 5, 2025, 07:39Paige Bingham: ''Be data-driven'', "Don't jump to conclusions", "Be intentional''- Few Gems Shared During Impactful Close the Gap session at Transform AF